Trial Profile

Ezabenlimab (BI 754091) and mDCF (Docetaxel, Cisplatin and 5-fluorouracil) Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. A Phase II Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Ezabenlimab (Primary) ; Fluorouracil (Primary) ; Capecitabine; Mitomycin
Indications Anal cancer; Carcinoma; Squamous cell cancer
Focus Proof of concept; Registrational; Therapeutic Use
Acronyms INTERACT-ION

Most Recent Events

20 Jan 2024 Preliminary results ( At analysis cut-off date,n=43 )presented at the 2024 Gastrointestinal Cancers Symposium
21 Dec 2023 Status changed from recruiting to active, no longer recruiting.
25 May 2023 Planned End Date changed from 5 Jul 2025 to 5 Jul 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com